不同糖皮质激素与脓毒症相关ARDS ICU患者死亡率的关联:基于MIMIC-IV数据库的回顾性队列研究
该回顾性队列研究分析MIMIC-IV数据库中896例脓毒症相关ARDS成人患者,按糖皮质激素种类和剂量(低剂量:<88 mg/天甲泼尼龙等效;高剂量:≥88 mg/天)分组。主要终点28天死亡率为49.4%(443/896)。与氢化可的松相比,甲泼尼龙(校正HR=0.71,95%CI 0.57-0.89)和地塞米松(校正HR=0.61,95%CI 0.44-0.86)与更低的28天死亡率相关;高剂量治疗与低剂量相比死亡率增加(校正HR=1.56,95%CI 1.23-1.97)。亚组分析和倾向性评分匹配结果一致。
要点
- 在896例脓毒症相关ARDS患者中,28天死亡率为49.4%(443例)。
- 与氢化可的松相比,甲泼尼龙与更低的28天死亡率相关(校正HR=0.71,95%CI 0.57-0.89)。
- 与氢化可的松相比,地塞米松与更低的28天死亡率相关(校正HR=0.61,95%CI 0.44-0.86)。
- 高剂量糖皮质激素治疗(≥88 mg/天甲泼尼龙等效)与低剂量(<88 mg/天)相比,28天死亡率增加(校正HR=1.56,95%CI 1.23-1.97)。
- 亚组分析和倾向性评分匹配分析结果与主要分析一致。
适用人群与场景
- MIMIC-IV数据库中脓毒症相关ARDS的成人患者。
- 按糖皮质激素种类和剂量分组:低剂量为<88 mg/天甲泼尼龙等效,高剂量为≥88 mg/天。
研究设计与关键结果
- 回顾性队列研究,纳入896例脓毒症相关ARDS成人患者,28天死亡443例(49.4%)。
- 与氢化可的松相比,甲泼尼龙校正HR=0.71(95%CI 0.57-0.89),地塞米松校正HR=0.61(95%CI 0.44-0.86),均与更低的28天死亡率相关。
- 高剂量治疗与低剂量相比,校正HR=1.56(95%CI 1.23-1.97),与死亡率增加相关。
- 亚组分析和倾向性评分匹配分析结果一致。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在脓毒症相关ARDS中,糖皮质激素的选择和剂量与生存相关;甲泼尼龙和地塞米松与氢化可的松相比与更低死亡率相关,而高剂量治疗与死亡率增加相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The comparative effectiveness of specific glucocorticoids (methylprednisolone, hydrocortisone, and dexamethasone) and the impact of dosing intensity on outcomes in sepsis-associated acute respiratory distress syndrome (ARDS) remain poorly characterized.
METHODS: This retrospective cohort study analyzed adults with sepsis-associated ARDS from the Medical Information Mart for Intensive Care IV database. Patients were classified by glucocorticoid type and dose (low-dose: <88 mg/day methylprednisolone equivalent; high-dose: ≥88 mg/day). The primary outcome was 28-day mortality, analyzed using multivariable Cox models with hazard ratio (HR) and 95% confidence interval (CI). Subgroup analyses and propensity score matching (PSM) were performed to validate the findings.
RESULTS: Among 896 patients, 443 (49.4%) died within 28 days. Compared with hydrocortisone, both methylprednisolone (adjusted HR = 0.71, 95% CI 0.57-0.89) and dexamethasone (adjusted HR = 0.61, 95% CI 0.44-0.86) were associated with lower 28-day mortality. High-dose therapy was associated with increased mortality versus low-dose (adjusted HR = 1.56, 95% CI 1.23-1.97). Results were consistent across subgroups and in PSM analyses.
CONCLUSION: In sepsis-associated ARDS, glucocorticoid selection and dose are associated with survival. Methylprednisolone and dexamethasone were associated with lower mortality compared with hydrocortisone, while high-dose therapy was linked to increased mortality.
参考来源
- Huang J, Xu Z, Huang J, et al. Association Between Different Glucocorticoids and Mortality in ICU Patients With Sepsis-Related Acute Respiratory Distress Syndrome: A Retrospective Cohort Study From MIMIC-IV Database. Shock. 2026. PMID: 41949761. doi:10.1097/SHK.0000000000002815
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。